R. Kratzke

Gwénaël Le Teuff, Elisabeth Brambilla, Lesley Seymour, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung Cancer and Lung Transplantation: A Review

R. Kratzke, J. Mathew, Robert A Kratzke, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

P. Jänne, E. Vokes, R. Kratzke, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression

R. Kratzke, D. Curiel, J. Geradts, 1998, Oncogene.

Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide.

R. Kratzke, S. Frizelle, M. Kratzke, 2008, Anticancer research.

Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304

S. Jewell, M. Edelman, E. Vokes, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors.

F. Kaye, R. Kratzke, G. Otterson, 1994, Oncogene.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304

M. Edelman, E. Vokes, R. Kratzke, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EUS-guided FNA for the diagnosis of advanced lung cancer.

R. Kratzke, R. Kelly, F. Lederle, 2006, Gastrointestinal endoscopy.

Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.

P. Jänne, M. Socinski, V. Miller, 2010 .

RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma.

S. Steinberg, J. Mulshine, R. Kratzke, 1994, Oncogene.

Quantification of Colorectal Cancer Micrometastases in Lymph Nodes by Nested and Real-Time Reverse Transcriptase-PCR Analysis for Carcinoembryonic Antigen

R. Kratzke, G. Niehans, D. Rothenberger, 2004, Clinical Cancer Research.

Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902.

R. Bueno, D. Harpole, R. Kratzke, 2013, The Journal of thoracic and cardiovascular surgery.

Bone morphogenetic protein 3B silencing in non-small-cell lung cancer

C. Plass, C. Morrison, H. Auer, 2004, Oncogene.

Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.

G. Patterson, D. Harpole, J. Herndon, 2005, Lung cancer.

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

R. Kratzke, Priya Kumar, A. Dudek, 2009, British Journal of Cancer.

Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system.

C. Le, R. Kratzke, M. Kirstein, 2009, Cancer letters.

Translational control: a target for cancer therapy.

R. Kratzke, S. Thumma, 2007, Cancer letters.

Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer.

R. Kratzke, B. Whitson, R. Bardales, 2007, The Annals of thoracic surgery.

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

Manish R. Patel, R. Kratzke, M. Peterson, 2018, Investigational New Drugs.

Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction.

R. Kratzke, G. Niehans, S. Frizelle, 1998, Chest.

Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).

A. Dudek, E. Vokes, R. Kratzke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

E. Vokes, R. Kratzke, G. Otterson, 2012, Lung cancer.

Rb and @16@4a Expression in Resected Non-Small Cell Lung Tumors'

D. Niewoehner, R. Kratzke, J. Geradts, 2000 .

In cerebrospinal fluid ER chaperones ERp57 and calreticulin bind β-amyloid

R. Kratzke, W. G. Wood, D. Olson, 2005 .

Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II

R. Kratzke, M. Escobedo, A. Sadiq, 2008, Investigational new drugs.

miR-1 induces growth arrest and apoptosis in malignant mesothelioma.

Chuong D. Hoang, C. Hoang, J. Shrager, 2013, Chest.

MicroRNA biomarkers in lung cancer: MiRacle or quagMiRe?

R. Kratzke, S. Yendamuri, 2011, Translational research : the journal of laboratory and clinical medicine.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

J. Pignon, L. Seymour, F. Shepherd, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Ras Pathway Activation in Malignant Mesothelioma

P. Janne, R. Kratzke, B. Whitson, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In vivo and In vitro Both Small Cell Lung Cancer − Transformed Phenotype in Non Repression of Cap-Dependent Translation Attenuates the Updated

R. Kratzke, M. Peterson, V. Polunovsky, 2006 .

Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.

R. Kratzke, M. Peterson, V. Polunovsky, 2006, Cancer research.

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC

R. Kratzke, A. Kulkarni, N. Fujioka, 2022, Lung cancer management.

Rb and p16INK4a expression in resected non-small cell lung tumors.

D. Niewoehner, R. Kratzke, J. Geradts, 1996, Cancer research.

Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells

R. Kratzke, J. Graff, A. Sadiq, 2015, Cancer Gene Therapy.

Do molecular markers predict survival in non-small-cell lung cancer?

D. Niewoehner, R. Kratzke, J. Jessurun, 1998, American journal of respiratory and critical care medicine.

A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.

F. Kaye, R. Kratzke, J. Horowitz, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma

R. Kratzke, V. Polunovsky, P. Bitterman, 2009, British Journal of Cancer.

Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.

D. Yee, R. Kratzke, B. Whitson, 2006, The Annals of thoracic surgery.

Dipyridamole mediated enhanced antiproliferative activity of 10‐ethyl‐10‐deazaaminopterin (10‐EDAM) against human lung cancer cell lines

B. Kramer, A. Gazdar, J. Mulshine, 1996, Journal of cellular biochemistry. Supplement.

Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.

C. Aliferis, Ping Yang, R. Kratzke, 2019, Clinical lung cancer.

Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.

R. Schilsky, D. Sugarbaker, D. Harpole, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).

P. Jänne, M. Socinski, V. Miller, 2013 .

Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion

R. Kratzke, M. Kirstein, J. D’Cunha, 2018, Cancer Chemotherapy and Pharmacology.

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.

R. Kratzke, A. Mitra, M. Kirstein, 2012, Pharmacogenomics.

Functional analysis at the Cys706 residue of the retinoblastoma protein.

F. Kaye, R. Kratzke, G. Otterson, 1992, The Journal of biological chemistry.

Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.

F. Kaye, R. Kratzke, G. Otterson, 1995, Journal of the National Cancer Institute.

Asbestos-Related Disease

R. Kratzke, Patti Kratzke, 2018 .

Targeting eukaryotic protein translation in mesothelioma.

R. Kratzke, 2017, Translational lung cancer research.

Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma

R. Kratzke, A. Saluja, J. D’Cunha, 2015, Genes & cancer.

Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report

E. Vokes, R. Kratzke, G. Otterson, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of in vitro chemosensitivity using human lung cancer cell lines

B. Kramer, R. Kratzke, 1996, Journal of cellular biochemistry. Supplement.

Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.

R. Kratzke, G. Niehans, J. Miller, 1999, Experimental hematology.

Wild-type and mutant retinoblastoma protein in paraffin sections.

R. Kratzke, S. Wen, J. Geradts, 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

CYFRA 21-1 (CYFRA) as a prognostic and predictive marker in advanced non-small cell lung cancer (NSCLC): CALGB 150304.

M. Edelman, E. Vokes, R. Kratzke, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lovastatin induces apoptosis in malignant mesothelioma cells.

R. Kratzke, V. Polunovsky, A. Tan, 1998, American journal of respiratory and critical care medicine.

In cerebrospinal fluid ER chaperones ERp57 and calreticulin bind beta-amyloid.

R. Kratzke, W. G. Wood, D. Olson, 2005, Biochemical and biophysical research communications.

Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.

R. Kratzke, J. Geradts, G. Niehans, 1995, Cancer research.

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer

R. Kratzke, S. Russell, M. Federspiel, 2015, Oncotarget.

Covid19 and cancer care: the end of the beginning

R. Kratzke, 2021, Journal of Cancer Metastasis and Treatment.

Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system

D. Yee, R. Kratzke, M. Kirstein, 2007, Cancer Chemotherapy and Pharmacology.

Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma

R. Kratzke, C. Wagner, Zeeshan Ahmad, 2020, Cancer Chemotherapy and Pharmacology.

Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells

R. Kratzke, C. Wagner, P. Bitterman, 2014, Investigational New Drugs.

Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.

M. Edelman, E. Vokes, R. Kratzke, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival of a patient with squamous cell carcinoma harboring NUT gene rearrangement.

R. Kratzke, M. J. Cameron, C. French, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues.

R. Kratzke, P. Gupta, Ajay Rawal, 2011, Archives of pathology & laboratory medicine.

Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407.

R. Govindan, E. Vokes, R. Kratzke, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of mesothioloma remains a conundrum.

R. Kratzke, 2013, Journal of the National Cancer Institute.

Survival of Lung Cancer Patients Dependent on the LOH Status for DMP1, ARF, and p53

R. Kratzke, E. A. Fry, Kazushi Inoue, 2020, International journal of molecular sciences.

Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Preclinical Models of Non-Small Cell Lung Cancer

R. Kratzke, R. Hebbel, B. Jacobson, 2020, Translational oncology.

Bone morphogenetic protein 3 B silencing in non-small-cell lung cancer

C. Plass, C. Morrison, H. Auer, 2004 .

Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation.

R. Kratzke, P. Bitterman, F. Farassati, 2011, International journal of oncology.

Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.

R. Kratzke, C. Wagner, P. Bitterman, 2013, Molecular pharmaceutics.

Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade

R. Kratzke, R. Shanley, A. Kulkarni, 2022, Cancer Immunology, Immunotherapy.

Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites.

F. Kaye, P. Johnston, R. Kratzke, 1993, Oncogene.

Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.

D. Yee, R. Kratzke, B. Whitson, 2006, The Annals of thoracic surgery.

Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis

D. Ferguson, R. Kratzke, B. Jacobson, 2012, Investigational New Drugs.

Novel oncolytic viral therapies in patients with thoracic malignancies

R. Kratzke, Zeeshan Ahmad, 2016, Oncolytic virotherapy.

Inhibition of mesothelioma cell growth in vitro by doxycycline.

R. Kratzke, J. Rubins, P. Bitterman, 2001, The Journal of laboratory and clinical medicine.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

B. Stish, R. Kratzke, D. Vallera, 2009, British Journal of Cancer.

Pyomyositis and hepatic abscess in association with Aeromonas hydrophila sepsis.

R. Kratzke, D. Golenbock, 1987, The American journal of medicine.

The pathogenesis of mesothelioma.

J. Testa, R. Kratzke, M. Carbone, 2002, Seminars in oncology.

Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity

David A Potter, D. Tindall, R. Kratzke, 2008, Molecular Cancer Therapeutics.

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

J. Pignon, E. Solary, L. Seymour, 2013, The New England journal of medicine.

Oncogenes in human lung cancer.

F. Kaye, R. Kratzke, E. Shimizu, 1992, Cancer treatment and research.

Recessive oncogenes in lung cancer.

F. Kaye, R. Kratzke, P. Lin, 1990, The American review of respiratory disease.

Recessive Oncogenes in Lung Cancer 1 • 2

F. Kaye, R. Kratzke, P. Lin, 1990 .

G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder

R. Kratzke, J. Geradts, G. Niehans, 1999, British Journal of Cancer.

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Gwénaël Le Teuff, Lesley Seymour, Ming-Sound Tsao, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.

J. Pignon, L. Seymour, F. Shepherd, 2013, Lung cancer.

LACE‐Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry‐based Biomarkers in Resected Non–small‐cell Lung Cancer

J. Pignon, L. Seymour, E. Brambilla, 2019, Clinical lung cancer.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

R. Govindan, J. Pignon, L. Seymour, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

D. Dingli, R. Kratzke, S. Russell, 2010, Cancer Gene Therapy.

Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.

F. Kaye, R. Kratzke, G. Otterson, 1994, Oncogene.

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

J. Pignon, L. Seymour, E. Brambilla, 2018, Translational lung cancer research.

Inactivation of p16INK4a expression in malignant mesothelioma by methylation.

R. Kratzke, Joan Zhou, L. Wong, 2002, Lung cancer.

Human lung carcinomas express Fas ligand.

D. Green, R. Kratzke, T. Brunner, 1997, Cancer research.

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

P. Jänne, J. Pignon, P. Hainaut, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix.

F. Kaye, R. Kratzke, G. Otterson, 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

P. Jänne, J. Pignon, P. Hainaut, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633.

Michael R. Green, P. Jänne, E. Vokes, 2010 .

ERBB2 amplifications in esophageal adenocarcinoma.

R. Kratzke, B. Jacobson, J. Fink, 2004, The Annals of thoracic surgery.

Prediction of Postoperative Recurrence-Free Survival in Non–Small Cell Lung Cancer by Using an Internationally Validated Gene Expression Model

Ranjana Mitra, Xianghua Luo, Monica Milani, 2011, Clinical Cancer Research.

Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.

Chuong D. Hoang, C. Hoang, R. Kratzke, 2004, Chest.

Targeting Eukaryotic Translation in Mesothelioma Cells with an eIF4E-Specific Antisense Oligonucleotide

R. Kratzke, J. Graff, B. Jacobson, 2013, PloS one.

Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer

R. Kratzke, M. Peterson, P. Bitterman, 2018, Cancer Gene Therapy.

Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma

R. Kratzke, S. Russell, B. Sorenson, 2017, Oncotarget.

Measles Vaccine Strains for Virotherapy of Non–Small-Cell Lung Carcinoma

R. Kratzke, S. Russell, M. Federspiel, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

P. Jänne, M. Socinski, M. Edelman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

I. Pastan, R. Kratzke, D. Vallera, 2023, Frontiers in Immunology.

Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)

W. Bshara, K. Kelly, D. Gandara, 2018, Journal of the National Cancer Institute.

Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B

R. Govindan, J. Herndon, R. Kratzke, 2005, Clinical Cancer Research.

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

G. Gordon, D. Sugarbaker, R. Bueno, 2006, Cancer research.

MicroRNA as Biomarkers of Malignant Mesothelioma

Chuong D. Hoang, C. Hoang, R. Kratzke, 2017 .

Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.

S. Mukherjee, M. West, H. Dressman, 2011, The New England journal of medicine.

Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance).

D. Sugarbaker, G. Patterson, F. Detterbeck, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer

R. Kratzke, Yunfang Li, G. Niehans, 2011, Anesthesia and analgesia.

Epigenetics of lung cancer.

Scott M Langevin, K. Kelsey, R. Kratzke, 2015, Translational research : the journal of laboratory and clinical medicine.

Minnelide: A Novel Therapeutic That Promotes Apoptosis in Non-Small Cell Lung Carcinoma In Vivo

R. Kratzke, A. Saluja, S. Vickers, 2013, PloS one.

Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC

R. Kratzke, A. Sadiq, B. Jacobson, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Carl Morrison, S. Jewell, C. Morrison, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Significance of Mucin and p53 Expression in Stage IB Non-small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633

E. Vokes, R. Kratzke, G. Strauss, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Annual Review of Advances in Non-small Cell Lung Cancer Research: A Report for the Year 2010

R. Govindan, R. Kratzke, T. Stinchcombe, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathway in Malignant Pleural Mesothelioma Functional Analysis of c-Met / Hepatocyte Growth Factor

G. Gordon, D. Sugarbaker, R. Bueno, 2005 .

Evidence for colorectal cancer micrometastases using reverse transcriptase-polymerase chain reaction analysis of MUC2 in lymph nodes.

R. Kratzke, G. Niehans, S. Frizelle, 2000, Cancer detection and prevention.

A 10‐Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non–Small Cell Lung Cancer

Leigh Murphy, Gaofeng Jia, Wayne Xu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

R. Govindan, L. Seymour, E. Brambilla, 2021, Translational lung cancer research.

Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stages IIB and III Non-small Cell Lung Cancer

T. Larson, R. Kratzke, K. Dragnev, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden.

Chuong D. Hoang, C. Hoang, R. Kratzke, 2004, The Journal of thoracic and cardiovascular surgery.

A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407--Early evaluation of feasibility and toxicity

R. Govindan, E. Vokes, R. Kratzke, 2008 .

Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904

E. Vokes, R. Kratzke, Mark R. Green, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells

Chuong D. Hoang, D. Yee, C. Hoang, 2004, Cancer Research.

Oncolytic Viral Therapy for Mesothelioma

R. Kratzke, D. Pease, 2017, Front. Oncol..

Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus

R. Kratzke, D. Curiel, J. Rubins, 2000, Cancer Gene Therapy.

Oncolytic virus therapy for cancer: the first wave of translational clinical trials.

R. Kratzke, M. Patel, 2013, Translational research : the journal of laboratory and clinical medicine.

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

Vadim J. Gurvich, R. Kratzke, M. Kirstein, 2013, British Journal of Cancer.

Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.

G. Patterson, J. Herndon, R. Kratzke, 2002, The Journal of thoracic and cardiovascular surgery.

Analysis of paired primary lung and lymph node tumor cells: a model of metastatic potential by multiple genetic programs.

Chuong D. Hoang, C. Hoang, R. Kratzke, 2005, Cancer detection and prevention.

Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas.

R. Kratzke, B. Whitson, Zhongze Li, 2010, The Journal of thoracic and cardiovascular surgery.

Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.

E. Vokes, R. Kratzke, H. Borghaei, 2020, Clinical lung cancer.

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

D. Sargent, S. George, E. Vokes, 2017, The oncologist.

Meet the new boss: lung cancer staging.

R. Kratzke, A. Begnaud, Abbie Begnaud, 2018, Journal of thoracic disease.

The Search for Novel Cancer Therapies : Catalytic Inhibition of Topoisomerase II by Substituted 9-aminoacridine Derivatives

R. Kratzke, B. Jacobson, Ryan G. Etchison, 2011 .

JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models

R. Kratzke, B. Jacobson, Yan Ji, 2019, Cancer Gene Therapy.

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

R. Govindan, E. Vokes, R. Kratzke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endoscopic ultrasound and positron emission tomography for lung cancer staging.

R. Kratzke, R. Kelly, F. Lederle, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.

R. Kratzke, M. Tessema, R. Bliss, 2013, Clinical lung cancer.

Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells.

Baolin Wu, S. Ikramuddin, C. Hoang, 2009, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity.

Baolin Wu, R. Kratzke, B. Whitson, 2008, The Annals of thoracic surgery.

A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)

E. Vokes, R. Kratzke, M. Kelley, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pilot Phase II Study of Gemcitabine and Vinorelbine in Patients with Recurrent or Refractory Small Cell Lung Cancer

R. Kratzke, R. Bliss, A. Dudek, 2004, Lung.

Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein

F. Kaye, R. Kratzke, G. Otterson, 1994, Molecular and cellular biology.

Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761.

J. Herndon, R. Kratzke, Mark R. Green, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

p16(INK4a) Peptide mimetics identified via virtual screening.

R. Kratzke, K. Mayo, Mark A. Klein, 2010, Bioorganic & medicinal chemistry letters.

Yin Yang Gene Expression Ratio Signature for Lung Cancer Prognosis

D. Yee, S. Banerji, R. Kratzke, 2013, PloS one.

Central intranodal blood vessel: a new EUS sign described in mediastinal lymph nodes.

R. Kratzke, R. Kelly, F. Lederle, 2007, Gastrointestinal endoscopy.

Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data.

R. Govindan, L. Seymour, E. Brambilla, 2023, Clinical lung cancer.

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

R. Kratzke, S. Patel, N. Pennell, 2016 .

Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival

R. Kratzke, G. Niehans, V. Morrison, 1999, Leukemia.

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

J. Pignon, E. Solary, L. Seymour, 2013, The New England journal of medicine.

Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer

R. Kratzke, Yunfang Li, G. Niehans, 2011, Anesthesia and analgesia.

Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria.

A. Dudek, R. Kratzke, R. Bliss, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response.

Chuong D. Hoang, Amanda Khuong, J. Shrager, 2013, Chest.

P-403 Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)

Michael R. Green, E. Vokes, R. Kratzke, 2005 .

Frontiers in Anti-Cancer Drug Discovery;

R. Kratzke, Ziyaur Rahman, M. Pešić, 2018 .

4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer

R. Kratzke, C. Wagner, Zeeshan Ahmad, 2020, Investigational New Drugs.

Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer

R. Kratzke, M. Peterson, P. Bitterman, 2018, Cancer Gene Therapy.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

S. Jewell, C. Morrison, M. Edelman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.

M. Edelman, E. Vokes, R. Kratzke, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304

M. Edelman, E. Vokes, R. Kratzke, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

R. Govindan, J. Pignon, L. Seymour, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer

R. Kratzke, C. Henke, B. Jacobson, 2023, International journal of molecular sciences.

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203.

M. Edelman, E. Vokes, R. Kratzke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)

E. Vokes, R. Kratzke, M. Kelley, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung Cancer and Lung Transplantation: A Review

R. Kratzke, J. Mathew, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system.

C. Le, D. Yee, R. Kratzke, 2007, Lung cancer.

Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity.

Baolin Wu, R. Kratzke, B. Whitson, 2008, The Annals of thoracic surgery.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

J. Pignon, L. Seymour, F. Shepherd, 2012 .